Adaptimmune Therapeutics plc (ADAPY)
OTCMKTS · Delayed Price · Currency is USD
0.0350
-0.0030 (-7.89%)
Jul 10, 2026, 11:22 AM EST
Adaptimmune Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 5.92 | - | 60.28 | 27.15 | 6.15 | |
Revenue Growth (YoY) | - | - | 122.05% | 341.50% | 55.36% |
Cost of Revenue | - | - | 126.51 | 127.73 | 111.09 |
Gross Profit | 5.92 | - | -66.23 | -100.58 | -104.94 |
Selling, General & Admin | 35.62 | 66.69 | 64.46 | 63.39 | 57.31 |
Research & Development | 48 | 111.63 | - | - | - |
Other Operating Expenses | -13.57 | -5.78 | - | - | - |
Operating Expenses | 70.05 | 172.54 | 64.46 | 63.39 | 57.31 |
Operating Income | -64.12 | -172.54 | -130.69 | -163.97 | -162.25 |
Interest Expense | -7.27 | -6.57 | - | - | - |
Interest & Investment Income | 1.65 | 6.6 | 5.96 | 1.54 | 1.1 |
Currency Exchange Gain (Loss) | 0.52 | - | -0.81 | -0.54 | 3.85 |
Other Non Operating Income (Expenses) | - | - | - | - | -0.01 |
EBT Excluding Unusual Items | -69.22 | -172.52 | -125.54 | -162.96 | -157.31 |
Merger & Restructuring Charges | - | - | -9.05 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | 0.01 |
Asset Writedown | -2.9 | -10.4 | - | - | - |
Other Unusual Items | - | - | 22.05 | - | - |
Pretax Income | -78.01 | -182.92 | -112.54 | -162.96 | -157.3 |
Income Tax Expense | - | -6.04 | 1.34 | 2.5 | 0.79 |
Earnings From Continuing Operations | -78.01 | -176.88 | -113.87 | -165.46 | -158.09 |
Earnings From Discontinued Operations | 103.21 | 105 | - | - | - |
Net Income | 25.21 | -71.88 | -113.87 | -165.46 | -158.09 |
Net Income to Common | 25.21 | -71.88 | -113.87 | -165.46 | -158.09 |
Shares Outstanding (Basic) | 263 | 252 | 201 | 161 | 156 |
Shares Outstanding (Diluted) | 272 | 252 | 201 | 161 | 156 |
Shares Change (YoY) | 7.97% | 25.48% | 24.73% | 3.47% | 9.37% |
EPS (Basic) | 0.10 | -0.28 | -0.57 | -1.03 | -1.01 |
EPS (Diluted) | 0.08 | -0.30 | -0.57 | -1.03 | -1.02 |
Free Cash Flow | -122.3 | -70 | -145.56 | -171.27 | 2.16 |
Free Cash Flow Per Share | -0.45 | -0.28 | -0.72 | -1.06 | 0.01 |
Gross Margin | 100.00% | - | -109.86% | - | - |
Operating Margin | -1082.41% | - | -216.81% | -603.97% | -2638.58% |
Profit Margin | 425.49% | - | -188.90% | -609.46% | -2570.99% |
Free Cash Flow Margin | -2064.40% | - | -241.47% | -630.86% | 35.05% |
EBITDA | -57.49 | -161.62 | -120.85 | -157.89 | -155.68 |
EBITDA Margin | - | - | -200.48% | - | - |
D&A For EBITDA | 6.63 | 10.92 | 9.84 | 6.08 | 6.57 |
EBIT | -64.12 | -172.54 | -130.69 | -163.97 | -162.25 |
EBIT Margin | - | - | -216.81% | - | - |
Revenue as Reported | - | - | 60.28 | 27.15 | 6.15 |